New study aims to crack the code of rare brain disease
NCT ID NCT05588167
First seen Jun 24, 2026 · Last updated Sep 01, 2026 · Updated 13 times
Summary
This study is creating the first large database for Niemann-Pick type C (NPC), a rare disease that damages the brain, liver, and spleen. Researchers will collect blood samples and medical records from 100 people with NPC to link their genes with their symptoms. The goal is to understand why the disease affects people so differently and to find clues for future treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this database could help researchers understand why NPC affects people differently and point toward new treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly help participants and may not lead to any new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2022
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals with Niemann-Pick Disease, type C
- Ages
-
3 months and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA; In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, any age, demographic or ethnic background will be eligible for this study 4. Diagnosis of NPC will be based on clinical, biochemical or molecular testing. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Unwilling to provide consent 2. Unable to provide biospecimen to obtain DNA 3. Unable to provide medical records or clinical data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Niemann-Pick disease, type C are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill shows promise for rare brain disorders in early trial
- Hope for rare brain disease: new drug trial targets movement and daily life
- Promising drug tested for rare liver disease in newborns
- Search for NPC clues could speed future treatments
- Scientists dive into rare cholesterol disorders to uncover clues
- New york program offers extra screening for 100,000 newborns